Ann: CardieX - Go-to-Market (GTM) & Product Development Update, page-61

Great post Quiltman.
Was thinking why would they have not tried this type of partnership sooner.

Possibly they went down the Nasdaq pathway as they saw a big payday at the end of it and then reality hit. Maybe stubbornly were not considering other alternatives as a Nasdaq listing would have kept them more in control and more reward.
Where this option would give less control but financial backing and seems to fit into the recent announcements about corporate governance and the adding a couple of directors on board.

Adding more staff, new directors , corporate governance. Feels like something is going on in the background.
Still speculation but either Alivecor or someone else seems to connect the pieces.

Not buying the wipe out capital raise discussion yet. Hopefully the time taken in suspension is to get the best deal. Am still assuming that Pulse is still the game changer that has been discussed and think this is an important equation in any capital raising requirements once the other issues are sorted out. Have seen a few recent rushed capital raises with hefty discounts but with no product or revenue for many years to come.
We have a FDA approved product ready to go once manufactured.
Shaking my head that Pulse was approved in April and still no product available.